Trial Profile
A Phase I Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Inhibitor BGB-3111 in Chinese Patients With B-cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Zanubrutinib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors BeiGene
- 15 Jun 2023 Results of pooled analysis from (BGB-3111-AU-003, BGB-3111-215, BGB-3111-216, BGB-3111-1002,BGB-3111-GA-101) assessing comparative summary of safety and efficacy data between the QD and BID regimens in patients with various B-cell malignancies presented at the 28th Congress of the European Haematology Association
- 28 Jul 2022 Results of a pooled post-hoc analysis assessing long-term follow-up outcomes of zanubrutinib in various lines of therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma from following clinical studies: NCT03189524, NCT02343120 and NCT03206918 published in the Advances in Therapy
- 01 Jul 2022 Results assessing safety and preliminary anti-tumour activity, published in the British Journal of Haematology.